Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23827954 | 0.90 | POLRMT (0.36) | POLRMTPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25077487 | 0.88 | POLRMT (0.36) | POLRMTPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25077335 | 0.86 | POLRMT (0.38) | POLRMTPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16708544 | 0.83 | — | — | |
| SCHEMBL25781049 | 0.82 | POLRMT (0.37) | POLRMTPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL19101840 | 0.82 | POLRMT (0.36) | POLRMTPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL25244021 | 0.82 | POLRMT (0.36) | POLRMTPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23827983 | 0.81 | POLRMT (0.47) | POLRMTDOT1L | |
| SCHEMBL27438725 | 0.81 | POLRMT (0.34) | POLRMT | |
| SCHEMBL26295326 | 0.80 | POLRMT (0.36) | POLRMTPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598916-A | Antiviral compounds | 吉利德科学公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-115135383-B | Antiviral compounds | 吉利德科学公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-4106876-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | POLRMT 76/4885PI4KA 218/4885PI4K2B 450/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | POLRMT 76/4885PI4KA 218/4885PI4K2B 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.